Impact of Resmetirom on Liver Histology and Metabolic Profiles in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Across the Spectrum of Thyroid Status: A Systematic Review
Archives of Endocrinology and Disorders · 02.11.2026 · 2 (3) · 1-9
DOI: 10.46889/aed.2026.2304 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Archives of Endocrinology and Disorders, online erschienen am 02.11.2026. Verfasst von Girin Ray und 1 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to metabolic syndrome and to thyroid dysfunction, particularly hypothyroidism, which may weaken Thyroid Hormone Receptor-β (THR-β) signaling in hepatocytes. Resmetirom, an oral liver-directed THR-β agonist, is the first drug approved for noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced fibrosis.
Objective
To synthesize the effects of resmetirom on liver histology, hepatic fat, lipid and other metabolic parameters, thyroid indices and safety in adults with MASLD, with attention to thyroid status.
Methods
PubMed, Scopus, Web of Science, the Cochrane Library and ClinicalTrials.gov were searched from inception to March 2025. Randomized phase 2 and phase 3 trials of resmetirom in adults with MASLD or MASH were eligible. The review followed PRISMA 2020, risk of bias was assessed with Cochrane RoB 2 and results were synthesized narratively because of heterogeneity in populations and endpoints.
Results
Three double-blind, placebo-controlled trials were included: a phase 2 trial (n = 125), MAESTRO-NAFLD-1 (n = 972 double-blind) and MAESTRO-NASH (n = 966). Resmetirom reduced hepatic fat on MRI-PDFF in all three (phase 2, week 12: −32.9% vs −10.4%). In MAESTRO-NASH, MASH resolution without worsening of fibrosis at week 52 occurred in 25.9% (80 mg) and 29.9% (100 mg) versus 9.7% with placebo and fibrosis improved by at least one stage in 24.2% and 25.9% versus 14.2%. LDL cholesterol fell by 13.6% to 16.3% at week 24, with parallel reductions in apolipoprotein B and triglycerides. Free T4 declined by roughly 16% to 21% while TSH and free T3 changed little, irrespective of levothyroxine use. Adverse events were mainly mild-to-moderate diarrhea and nausea. Participants with untreated hypothyroidism were excluded and efficacy was not reported by thyroid-status subgroup.
Conclusion
Resmetirom improves liver fat, histology and atherogenic lipids with an acceptable safety profile in MASLD/MASH. Evidence for patients with stable, treated hypothyroidism is reassuring for thyroid-axis safety but does not yet establish thyroid-specific efficacy; dedicated analyses in hypothyroid cohorts and longer follow-up are needed.
Zitieren
APA
Ray, G., & Sanyal, D. (2026). Impact of Resmetirom on Liver Histology and Metabolic Profiles in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Across the Spectrum of Thyroid Status: A Systematic Review. Archives of Endocrinology and Disorders, 2(3), 1-9. https://doi.org/10.46889/aed.2026.2304
Vancouver
Ray G, Sanyal D. Impact of Resmetirom on Liver Histology and Metabolic Profiles in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Across the Spectrum of Thyroid Status: A Systematic Review. Archives of Endocrinology and Disorders. 2026;2(3):1-9. doi:10.46889/aed.2026.2304
BibTeX
@article{Ray2026,
author = {Ray, Girin and Sanyal, Debmalya},
title = {Impact of Resmetirom on Liver Histology and Metabolic Profiles in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Across the Spectrum of Thyroid Status: A Systematic Review},
journal = {Archives of Endocrinology and Disorders},
year = {2026},
volume = {2},
number = {3},
pages = {1--9},
doi = {10.46889/aed.2026.2304}
}
EUVIMED